ATE505541T1 - Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai - Google Patents
Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnaiInfo
- Publication number
- ATE505541T1 ATE505541T1 AT05813245T AT05813245T ATE505541T1 AT E505541 T1 ATE505541 T1 AT E505541T1 AT 05813245 T AT05813245 T AT 05813245T AT 05813245 T AT05813245 T AT 05813245T AT E505541 T1 ATE505541 T1 AT E505541T1
- Authority
- AT
- Austria
- Prior art keywords
- rnai
- replication
- intermediate products
- strand
- counter
- Prior art date
Links
- 230000010076 replication Effects 0.000 title abstract 3
- 108091030071 RNAI Proteins 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 239000013067 intermediate product Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 230000009368 gene silencing by RNA Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61306504P | 2004-09-24 | 2004-09-24 | |
| PCT/US2005/034371 WO2006036872A2 (en) | 2004-09-24 | 2005-09-26 | Targeting opposite strand replication intermediates of single-stranded viruses by rnai |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505541T1 true ATE505541T1 (de) | 2011-04-15 |
Family
ID=36119488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05813245T ATE505541T1 (de) | 2004-09-24 | 2005-09-26 | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090137039A1 (de) |
| EP (3) | EP2325314B1 (de) |
| JP (1) | JP2008514202A (de) |
| AT (1) | ATE505541T1 (de) |
| AU (1) | AU2005289633A1 (de) |
| CA (2) | CA2581224C (de) |
| DE (1) | DE602005027479D1 (de) |
| ES (1) | ES2362670T3 (de) |
| WO (1) | WO2006036872A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002918A2 (en) | 2007-06-22 | 2008-12-31 | Nucleonics, Inc. | Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use |
| EA201790534A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии |
| AU2016295168B2 (en) * | 2015-07-17 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| EP3548005A4 (de) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosome zur ausgabe von therapeutischen wirkstoffen |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| CN115725656B (zh) * | 2021-09-01 | 2026-01-16 | 联邦生物科技(珠海横琴)有限公司 | 一种以细胞质rna病毒为载体递送干扰rna的方法 |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2024137857A1 (en) * | 2022-12-22 | 2024-06-27 | Tevard Biosciences, Inc. | Conditional expression of a gene of interest by convergent promoters and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US529976A (en) | 1894-11-27 | tranquilli | ||
| JPH09107970A (ja) * | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | Ｃ型肝炎ウイルス由来核酸、該核酸を用いたウイルスの検出方法 |
| US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US20040127446A1 (en) * | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| US6284458B1 (en) * | 1992-09-10 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| JPH10503364A (ja) | 1994-05-10 | 1998-03-31 | ザ ジェネラル ホスピタル コーポレーション | Ｃ型肝炎ウイルスのアンチセンス阻害 |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US5874565A (en) | 1995-08-29 | 1999-02-23 | Washington University | Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| US5851804A (en) | 1996-05-06 | 1998-12-22 | Apollon, Inc. | Chimeric kanamycin resistance gene |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
| WO1999021591A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
| AU3000499A (en) | 1998-03-16 | 1999-10-11 | Procter & Gamble Company, The | Method of reducing cellulite in mammalian skin |
| WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US6533250B2 (en) | 1999-10-15 | 2003-03-18 | W. Eugene Arthur | Energy dissipating system for a concrete roadway barrier |
| US20040209831A1 (en) * | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
| AU2002321859A1 (en) | 2001-08-03 | 2003-02-24 | Michael Van Der Sleesen | Protective garment |
| US7103761B2 (en) | 2001-08-07 | 2006-09-05 | Hewlett-Packard Development Company, Lp. | Server system with multiple management user interfaces |
| DE10163098B4 (de) * | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| CA2464464A1 (en) | 2001-10-22 | 2003-05-01 | Nucleonics Inc. | Transfection kinetics and structural promoters |
| CA2457528C (en) * | 2002-02-20 | 2011-07-12 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) |
| JP2003269028A (ja) | 2002-03-18 | 2003-09-25 | Aisin Seiki Co Ltd | ドアロック解除装置 |
| AU2003266014B2 (en) | 2002-05-06 | 2009-05-14 | Alnylam Pharmaceuticals, Inc. | Methods for delivery of nucleic acids |
| CA2884658A1 (en) * | 2002-07-26 | 2004-02-05 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| EP1540004A4 (de) | 2002-07-31 | 2007-10-03 | Nucleonics Inc | Doppelstrang-rna-strukturen und -konstrukte sowie verfahren zur erzeugung und verwendung davon |
| WO2004029213A2 (en) * | 2002-09-28 | 2004-04-08 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering rna and short hairpin rna |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| CA2502649A1 (en) | 2002-10-18 | 2004-04-29 | Nucleonics Inc. | Double-stranded rna structures and constructs, and methods for generating and using the same |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| WO2004078974A1 (ja) * | 2003-01-24 | 2004-09-16 | Tokyo Metropolitan Organization For Medical Research | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| ATE554185T1 (de) | 2003-02-27 | 2012-05-15 | Alnylam Pharmaceuticals Inc | Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen |
| US8350021B2 (en) * | 2003-06-12 | 2013-01-08 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| JP2007503205A (ja) | 2003-08-22 | 2007-02-22 | ニュークレオニクス・インコーポレイテッド | 多コンパートメント真核生物発現系 |
| KR101337579B1 (ko) | 2004-03-05 | 2013-12-06 | 베니텍 리미티드 | ＲＮＡｉ 제제의 동시 전달을 위한 다중 프로모터 발현 카세트 |
| CA2592099A1 (en) * | 2004-12-22 | 2006-06-29 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
-
2005
- 2005-09-26 ES ES05813245T patent/ES2362670T3/es active Active
- 2005-09-26 CA CA2581224A patent/CA2581224C/en not_active Expired - Lifetime
- 2005-09-26 EP EP10181465.5A patent/EP2325314B1/de not_active Expired - Lifetime
- 2005-09-26 CA CA2824308A patent/CA2824308A1/en not_active Abandoned
- 2005-09-26 DE DE602005027479T patent/DE602005027479D1/de active Active
- 2005-09-26 EP EP14165247.9A patent/EP2772541A3/de not_active Withdrawn
- 2005-09-26 AU AU2005289633A patent/AU2005289633A1/en not_active Abandoned
- 2005-09-26 WO PCT/US2005/034371 patent/WO2006036872A2/en not_active Ceased
- 2005-09-26 JP JP2007533698A patent/JP2008514202A/ja active Pending
- 2005-09-26 AT AT05813245T patent/ATE505541T1/de not_active IP Right Cessation
- 2005-09-26 EP EP05813245A patent/EP1797185B1/de not_active Expired - Lifetime
-
2008
- 2008-08-29 US US12/201,499 patent/US20090137039A1/en not_active Abandoned
-
2010
- 2010-03-01 US US12/714,949 patent/US9198927B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP2325314B1 (de) | 2014-08-20 |
| US9198927B2 (en) | 2015-12-01 |
| EP1797185B1 (de) | 2011-04-13 |
| EP2772541A2 (de) | 2014-09-03 |
| DE602005027479D1 (de) | 2011-05-26 |
| CA2581224C (en) | 2013-11-19 |
| ES2362670T3 (es) | 2011-07-11 |
| US20090137039A1 (en) | 2009-05-28 |
| WO2006036872A2 (en) | 2006-04-06 |
| EP1797185A2 (de) | 2007-06-20 |
| EP2325314A2 (de) | 2011-05-25 |
| EP2772541A3 (de) | 2014-09-24 |
| JP2008514202A (ja) | 2008-05-08 |
| CA2824308A1 (en) | 2006-04-06 |
| US20100267805A1 (en) | 2010-10-21 |
| EP2325314A3 (de) | 2011-11-23 |
| CA2581224A1 (en) | 2006-04-06 |
| WO2006036872A3 (en) | 2006-08-17 |
| AU2005289633A1 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008033466A3 (en) | Compositions and methods for treatment of viral diseases | |
| WO2010021681A3 (en) | Compositions and methods for treatment of viral diseases | |
| WO2007053696A3 (en) | Rnai inhibition of influenza virus replication | |
| DK2230304T3 (da) | IRNA-modulering af RSV og terapeutiske anvendelser deraf | |
| NO20071162L (no) | Heterosykliske antivirale forbindelser | |
| ATE518967T1 (de) | Verfahren zur verhinderung einer virus-zelle- fusion durch hemmen der funktion des fusionsinitiierungsbereichs in rna-viren mit klasse-i-membranfusogenen hüllproteinen | |
| WO2010107739A3 (en) | Methods and compositions of treating a flaviviridae family viral infection | |
| WO2008133753A3 (en) | Anti-viral compounds | |
| ATE494373T2 (de) | Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle | |
| WO2009039248A8 (en) | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection | |
| EA200700243A1 (ru) | Способы лечения гепатита с | |
| WO2009121004A3 (en) | Neutralizing molecules to viral antigens | |
| WO2010047830A3 (en) | Agents for hcv treatment | |
| WO2009136979A3 (en) | Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof | |
| ATE505541T1 (de) | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai | |
| JP2011519414A5 (de) | ||
| WO2010055164A3 (en) | Isoquinolone derivatives as inhibitors of plavivirus replication | |
| EP2092078A4 (de) | Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer | |
| AU2021288648A8 (en) | Conjugate of double-stranded siRNA analogue | |
| WO2010107742A3 (en) | Methods and compositions of treating a flaviviridae family viral infection | |
| WO2010014248A3 (en) | Antiviral activity of the protein scytovirin and methods of use | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| UY29225A1 (es) | Compuesto 5-nitro-nucleosidos para tratar infecciones virales | |
| PH12022553394A1 (en) | Conjugate of double-stranded sirna analogue | |
| GB2463584A (en) | Carbohydrate-lipid constructs and their use in preventing or treating viral infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |